Fruitflow® is a patented, scientifically-proven tomato extract which inhibits platelet aggregation, a known cause of heart attack, stroke and venous thrombosis.  Discovered by Professor Asim Dutta Roy at the Rowett Institute in 1999, the technology has been developed by the Provexis team in recent years. This development programme includes eight clinical trials (to date), regulatory clearance in both the EU and USA, the publication of clinical proof in highly-regarded peer-review scientific journals, and patent protection in major global territories.

The product is commercially-ready for delivery in a wide range of food, beverage and dietary supplement formats. Future claim areas under development include deep vein thrombosis, metabolic syndrome and type-II diabetes.

NSP#3G

Provexis is the 75% shareholder in a joint venture with the University of Liverpool which owns the NSP#3G plantain extract for the treatment of Inflammatory Bowel Disease. Current work is focused on increasing the remission time in Crohn’s Disease patients and following a recent first phase healthy human trial, the company will carry out patient trials from the second half of 2008.

Helicobacter pylori

Provexis has recently taken an option on IP developed at the University of Manchester for the treatment and prevention of peptic ulcers that specifically targets the causative agent, the bacterium helicobacter pylori. Work in late 2008 and early 2009 will be focused on developing a stabilised extract, prior to commencing a clinical trial programme.